30-Aug-2024
AC Immune’s Diagnostic Achieves FDA Fast Track Status
TipRanks (Wed, 28-Aug 9:27 AM ET)
Globe Newswire (Wed, 28-Aug 9:00 AM ET)
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Globe Newswire (Tue, 6-Aug 7:00 AM ET)
Globe Newswire (Wed, 31-Jul 8:30 AM ET)
AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease
Globe Newswire (Thu, 25-Jul 7:00 AM ET)
Globe Newswire (Tue, 16-Jul 7:00 AM ET)
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ac Immune SA trades on the NASDAQ stock market under the symbol ACIU.
As of August 30, 2024, ACIU stock price was flat at $3.23 with 41,967 million shares trading.
ACIU has a beta of 0.93, meaning it tends to be less sensitive to market movements. ACIU has a correlation of 0.02 to the broad based SPY ETF.
ACIU has a market cap of $319.44 million. This is considered a Small Cap stock.
In the last 3 years, ACIU stock traded as high as $12.61 and as low as $1.68.
The top ETF exchange traded funds that ACIU belongs to (by Net Assets): IBB, SBIO, QQQS, BIB, IBBQ.
ACIU has underperformed the market in the last year with a price return of +0.6% while the SPY ETF gained +26.5%. ACIU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.6% and -4.2%, respectively, while the SPY returned +8.2% and +1.7%, respectively.
ACIU support price is $3.06 and resistance is $3.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACIU stock will trade within this expected range on the day.